{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:17:29Z","timestamp":1788387449171,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-82795-9","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T08:26:20Z","timestamp":1735374380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy"],"prefix":"10.1038","volume":"14","author":[{"given":"Jim","family":"Abi Frem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Khazzeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Allaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caren","family":"Doueiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racha","family":"Ghoussaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina A.","family":"Kanafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"issue":"1","key":"82795_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","volume":"1","author":"GH Lyman","year":"2003","unstructured":"Lyman, G. H. & Kuderer, N. M. Epidemiology of febrile neutropenia. Support Cancer Ther. 1(1), 23\u201335 (2003).","journal-title":"Support Cancer Ther."},{"issue":"1","key":"82795_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1182\/hematology.2020000098","volume":"2020","author":"C Logan","year":"2020","unstructured":"Logan, C., Koura, D. & Taplitz, R. Updates in infection risk and management in acute leukemia. Hematol. Am. Soc. Hematol. Educ. Program. 2020(1), 135\u2013139 (2020).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"82795_CR3","doi-asserted-by":"crossref","unstructured":"Baden, L. R. et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc Netw. 14(7), 882\u2013913 (2016).","DOI":"10.6004\/jnccn.2016.0093"},{"key":"82795_CR4","doi-asserted-by":"crossref","unstructured":"Stern, A. et al. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst. Rev. 1(1), CD012184 (2019).","DOI":"10.1002\/14651858.CD012184.pub2"},{"issue":"2","key":"82795_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.idc.2019.02.003","volume":"33","author":"G Satyanarayana","year":"2019","unstructured":"Satyanarayana, G. Work-up for fever during neutropenia for both the stem cell transplant recipient and the hematologic malignancy patient. Infect. Dis. Clin. N. Am. 33(2), 381\u2013397 (2019).","journal-title":"Infect. Dis. Clin. N. Am."},{"issue":"4","key":"82795_CR6","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 52(4), e56-93 (2011).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"82795_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/jac\/dkm514","volume":"61","author":"C Cattaneo","year":"2008","unstructured":"Cattaneo, C. et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J. Antimicrob. Chemother. 61(3), 721\u2013728 (2008).","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"82795_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/sj.bmt.1705677","volume":"39","author":"AL Oliveira","year":"2007","unstructured":"Oliveira, A. L. et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 39(12), 775\u2013781 (2007).","journal-title":"Bone Marrow Transplant."},{"key":"82795_CR9","unstructured":"Ghosn, M. et al. Infections in cancer patients with granulocytopenia. Retrospective studies of 59 febrile episodes with hospitalization. J. Med. Liban. 42(3), 117\u2013122 (1994)."},{"issue":"3","key":"82795_CR10","first-page":"136","volume":"48","author":"F Hamzeh","year":"2000","unstructured":"Hamzeh, F., Kanj, S. S. & Uwaydah, M. Febrile neutropenia in cancer patients in a tertiary care medical center in Lebanon: microbial spectrum and outcome. J. Med. Liban. 48(3), 136\u2013142 (2000).","journal-title":"J. Med. Liban."},{"issue":"5","key":"82795_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijid.2006.12.008","volume":"11","author":"ZA Kanafani","year":"2007","unstructured":"Kanafani, Z. A. et al. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade. Int. J. Infect. Dis. 11(5), 450\u2013453 (2007).","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"82795_CR12","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1016\/S1473-3099(18)30414-6","volume":"18","author":"RA Moghnieh","year":"2018","unstructured":"Moghnieh, R. A. et al. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect. Dis. 18(12), e379\u2013e394 (2018).","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"82795_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jiph.2020.11.006","volume":"14","author":"M Moussally","year":"2021","unstructured":"Moussally, M. et al. Prevalence of antibiotic-resistant organisms among hospitalized patients at a tertiary care center in Lebanon, 2010\u20132018. J. Infect. Public Health 14(1), 12\u201316 (2021).","journal-title":"J. Infect. Public Health"},{"issue":"6","key":"82795_CR14","doi-asserted-by":"publisher","first-page":"106335","DOI":"10.1016\/j.ijantimicag.2021.106335","volume":"57","author":"D Clerici","year":"2021","unstructured":"Clerici, D. et al. The place of ceftazidime\/avibactam and ceftolozane\/tazobactam for therapy of haematological patients with febrile neutropenia. Int. J. Antimicrob. Agents 57(6), 106335 (2021).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"82795_CR15","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","volume":"10","author":"A Soriano","year":"2021","unstructured":"Soriano, A. et al. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect. Dis. Ther. 10(4), 1989\u20132034 (2021).","journal-title":"Infect. Dis. Ther."},{"key":"82795_CR16","doi-asserted-by":"publisher","first-page":"986938","DOI":"10.1155\/2014\/986938","volume":"2014","author":"P Villafuerte-Gutierrez","year":"2014","unstructured":"Villafuerte-Gutierrez, P., Villalon, L., Losa, J. E. & Henriquez-Camacho, C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv. Hematol. 2014, 986938 (2014).","journal-title":"Adv. Hematol."},{"issue":"5","key":"82795_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 40(5), 373\u2013383 (1987).","journal-title":"J. Chron. Dis."},{"issue":"8","key":"82795_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8), 801\u2013810 (2016).","journal-title":"JAMA"},{"issue":"3","key":"82795_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1159\/000503095","volume":"12","author":"F Azam","year":"2019","unstructured":"Azam, F. et al. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep. Oncol. 12(3), 728\u2013736 (2019).","journal-title":"Case Rep. Oncol."},{"key":"82795_CR20","doi-asserted-by":"crossref","unstructured":"Hansen, B. A. et al. Febrile neutropenia in acute leukemia. epidemiology, etiology, pathophysiology and treatment. Mediterr. J. Hematol. Infect Dis. 12(1), e2020009 (2020).","DOI":"10.4084\/mjhid.2020.009"},{"issue":"3","key":"82795_CR21","doi-asserted-by":"publisher","first-page":"e13842","DOI":"10.1111\/tid.13842","volume":"24","author":"M Akhmedov","year":"2022","unstructured":"Akhmedov, M. et al. Incidence, etiology, risk factors, and outcomes of pre-engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation. Transpl. Infect. Dis. 24(3), e13842 (2022).","journal-title":"Transpl. Infect. Dis."},{"issue":"3","key":"82795_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5144\/0256-4947.2023.172","volume":"43","author":"K Binkhamis","year":"2023","unstructured":"Binkhamis, K. et al. Prevalence of bacterial bloodstream infections and association between neutropenia and 30-day mortality among oncology inpatients at a university hospital in Saudi Arabia. Ann. Saudi Med. 43(3), 172\u2013178 (2023).","journal-title":"Ann. Saudi Med."},{"issue":"1","key":"82795_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jiph.2023.11.017","volume":"17","author":"H El Omri","year":"2024","unstructured":"El Omri, H. et al. Dissecting bloodstream infections in febrile neutropenic patients with hematological malignancies, a decade-long single center retrospective observational study (2009\u20132019). J. Infect. Public Health 17(1), 152\u2013162 (2024).","journal-title":"J. Infect. Public Health"},{"issue":"3","key":"82795_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jiph.2018.12.006","volume":"12","author":"JA Al-Tawfiq","year":"2019","unstructured":"Al-Tawfiq, J. A. et al. Epidemiology and source of infection in patients with febrile neutropenia: a ten-year longitudinal study. J. Infect Public Health 12(3), 364\u2013366 (2019).","journal-title":"J. Infect Public Health"},{"issue":"3","key":"82795_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1128\/JCM.42.3.1089-1094.2004","volume":"42","author":"J Rodriguez-Bano","year":"2004","unstructured":"Rodriguez-Bano, J. et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J. Clin. Microbiol. 42(3), 1089\u20131094 (2004).","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"82795_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","volume":"76","author":"M Mikulska","year":"2018","unstructured":"Mikulska, M. et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J. Infect. 76(1), 20\u201337 (2018).","journal-title":"J. Infect."},{"issue":"6","key":"82795_CR27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/10428194.2023.2197532","volume":"64","author":"M Akhmedov","year":"2023","unstructured":"Akhmedov, M. et al. Impact of fluoroquinolone administration and gut mucosal colonization on the risk of pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation. Leuk Lymphoma 64(6), 1102\u20131111 (2023).","journal-title":"Leuk Lymphoma"},{"key":"82795_CR28","doi-asserted-by":"crossref","unstructured":"Satlin, M. J. & Walsh, T. J. Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: three major threats to hematopoietic stem cell transplant recipients. Transpl. Infect. Dis. 19, 6 (2017).","DOI":"10.1111\/tid.12762"},{"key":"82795_CR29","doi-asserted-by":"crossref","unstructured":"Averbuch, D0 et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98(12), 1826\u20131835 (2013).","DOI":"10.3324\/haematol.2013.091025"},{"issue":"14","key":"82795_CR30","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz, R. A. et al. Outpatient management of fever and neutropenia in adults treated for malignancy: american society of clinical oncology and infectious diseases Society of America Clinical Practice guideline update. J. Clin. Oncol. 36(14), 1443\u20131453 (2018).","journal-title":"J. Clin. Oncol."},{"key":"82795_CR31","doi-asserted-by":"crossref","unstructured":"Groll, A. H. et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 15(8), e327-40 (2014).","DOI":"10.1016\/S1470-2045(14)70017-8"},{"issue":"3","key":"82795_CR32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ijantimicag.2018.04.017","volume":"52","author":"AL Khoo","year":"2018","unstructured":"Khoo, A. L. et al. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia. Int. J. Antimicrob. Agents 52(3), 350\u2013357 (2018).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"82795_CR33","unstructured":"Sonya, K. et al. Overcoming resistance: antibiotic guidance for multidrug-resistant febrile neutropenia in patients with cancer. J. Hematol. Oncol. Pharm. 2021, 11 (2021)."},{"issue":"5","key":"82795_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s10096-020-04096-z","volume":"40","author":"S Ogura","year":"2021","unstructured":"Ogura, S. et al. Characteristics of gram-negative bacteremia during febrile neutropenia among allogeneic hematopoietic stem cell transplant recipients on levofloxacin prophylaxis. Eur. J. Clin. Microbiol. Infect. Dis. 40(5), 941\u2013948 (2021).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"82795_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijregi.2021.09.002","volume":"1","author":"C Sereeaphinan","year":"2021","unstructured":"Sereeaphinan, C., Kanchanasuwan, S. & Julamanee, J. Mortality-associated clinical risk factors in patients with febrile neutropenia: a retrospective study. IJID Reg. 1, 5\u201311 (2021).","journal-title":"IJID Reg."},{"issue":"1","key":"82795_CR36","first-page":"59","volume":"11","author":"C Wanitpongpun","year":"2021","unstructured":"Wanitpongpun, C. et al. Clinical factors predictive of mortality in acute leukemia patients with febrile neutropenia. Am. J. Blood Res. 11(1), 59\u201365 (2021).","journal-title":"Am. J. Blood Res."},{"key":"82795_CR37","doi-asserted-by":"crossref","unstructured":"Nattamol, H. et al. Prognostic factors for mortality with febrile neutropenia in hospitalized patients. Southwest Respir. Crit. Care Chron. 3, 9 (2015).","DOI":"10.12746\/swrccc2015.0309.112"},{"key":"82795_CR38","doi-asserted-by":"crossref","unstructured":"Jorgensen, S. C. J. et al. Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections. Open Forum Infect Dis. 6(12), ofz522 (2019).","DOI":"10.1093\/ofid\/ofz522"},{"key":"82795_CR39","doi-asserted-by":"crossref","unstructured":"Herrera, F. et al. Ceftazidime-avibactam improves outcomes in high-risk neutropenic patients with Klebsiella pneumoniae carbapenemase-producing enterobacterales bacteremia. Microorganisms 12, 1 (2024).","DOI":"10.3390\/microorganisms12010195"},{"key":"82795_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","volume":"59","author":"JJ Cast\u00f3n","year":"2017","unstructured":"Cast\u00f3n, J. J. et al. Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int. J. Infect. Dis. 59, 118\u2013123 (2017).","journal-title":"Int. J. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82795-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T21:29:31Z","timestamp":1735421371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["82795"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-82795-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"All experimental protocols were approved by the Institutional Review Board at the American University of Beirut.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval statement"}},{"value":"Since this was a retrospective descriptive study, informed consent was waived by the Institutional Review Board at the American University of Beirut.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"31322"}}